One of the main shortcomings of the clinical use of Hematopoietic Stem Cells (HSCs) is the limited number of cells that can be safely harvested from a patient.
Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.